Maria A. Gonzalez-Sala - Publications

Socioeconomic disparities in sarcoma diagnosis, expert center access, and advocacy group awareness: a multicenter study in Southern Europe.

Journal: The oncologist

Published: July 23, 2026

A randomised non-comparative phase II study of atezolizumab, bevacizumab and chemotherapy in EGFR-mutant NSCLC with acquired resistance - The ETOP 15-19 ABC-lung trial.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: December 06, 2024

Evaluation of the effectiveness and safety of avapritinib in real-world Spanish cases with gastrointestinal stromal tumor and D842V-PDGFRA mutation.

Journal: The oncologist

Published: October 16, 2024

Leveraging Large Language Models for Precision Monitoring of Chemotherapy-Induced Toxicities: A Pilot Study with Expert Comparisons and Future Directions.

Journal: Cancers

Published: July 03, 2024

BRAF mutational status is associated with survival outcomes in locally advanced resectable and metastatic NSCLC.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: February 19, 2024

The S-REAL study: Spanish real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: November 08, 2023

Addressing lung cancer screening eligibility in Spain using 2013 and 2021 US Preventive Service Task Force criteria: cross-sectional study.

Journal: ERJ open research

Published: July 10, 2023

Changes in lung cancer survival by TNM stage in the Basque country from 2003 to 2014 according to period of diagnosis.

Journal: Cancer epidemiology

Published: May 16, 2019

Prolonged survival with erlotinib followed by afatinib in a caucasian smoker with metastatic, poorly differentiated large cell carcinoma of the lung: a case report.

Journal: Cancer biology & therapy

Published: July 18, 2015